Program
ALN-ANG3
Its studies are mostly in Diabetic Nephropathies · Hyperlipidemias, led by Regeneron Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 22 open or running | phase 2since Nov 21, 2025 | Jun 5, 2024 | Dec 4, 2026phase 1 · NCT06452771 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 5, 2024First study: phase 1 study in Healthy Volunteers With HyperlipidemiaFirst studyNCT06452771 · 59 enrolled · New Zealand
- Nov 21, 2025Phase 2 study in Diabetic NephropathiesPhase 2 reachedNCT07271186 · 195 planned · United States
Ahead
- Dec 4, 2026Primary completion: phase 1 study in Healthy Volunteers With HyperlipidemiaNCT06452771
- Oct 13, 2028Primary completion: phase 2 study in Diabetic NephropathiesNCT07271186
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07271186Diabetic Nephropathies · United States | 2 | Recruiting | Oct 13, 2028 | 195 |
| NCT06452771Healthy Volunteers With Hyperlipidemia · New Zealand | 1 | Active, not recruiting | Dec 4, 2026 | 59 |
How it is read
Names in the registry
- “ALN-ANG3”, 2 entries
Conditions, from the studies’ own filings
- Diabetic Nephropathies, 1 study
- Hyperlipidemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.